HR Execs on the Move

The Guild

www.theguild.co

 
Whether you travel because you want to or because you have to, being away from home shouldn`t mean pressing pause on life. With the comforts of the community, the pleasures of home, and the perks of prime locations, The Guild lets you keep on living your best life--no matter where the road takes you.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.theguild.co
  • 1209 E Cesar Chavez
    Austin, TX USA 78702
  • Phone: 512.623.7480

Executives

Name Title Contact Details
Robert Mendoza
Corporate Director of Sales Profile

Similar Companies

AcelRx

AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.

Xradia

Xradia designs and manufactures a suite of ultra high resolution 3D x-ray microscopes and fluorescence imaging systems for non-destructive imaging of embedded internal structures.

Aperio Technologies Inc.

Aperio is committed to attracting and retaining the most highly qualified candidates available. As an Aperio employee you will be consistently challenged to deliver your best.

Apria Healthcare

Apria Healthcare is a Jacksonville, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.